SUBSCRIBE
SUBSCRIBE
News   Drug Development

Amgen Develops Six Cancer Drugs as Anemia Decline Hurts Revenue

April 11, 2008 | 
1 min read

April 11 (Bloomberg) -- Amgen Inc., the world’s largest biotechnology company by sales, is developing six cancer drugs to help recover from a decline in its anemia products.

Preclinical
Amgen
MORE ON THIS TOPIC
Pictured: Entrance to Pfizer's office in Belgium
Breast cancer
Pfizer, Arvinas Post Mixed Late-Stage Breast Cancer Data for Closely Watched PROTAC Drug
March 11, 2025
 · 
2 min read
 · 
Tristan Manalac
2D illustration showing scientists' hands editing a DNA strand
Gene editing
Beam’s Gene Editor Achieves ‘First Ever’ Genetic Correction in AATD
March 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Modern collage with human heart and hands stock illustration
Cardiovascular disease
Deep Dive: Cardiovascular Disease Back in the Spotlight
March 10, 2025
 · 
2 min read
 · 
Heather McKenzie
Tiny doctors examining heart health flat vector illustration. Cartoon medical specialists doing checkup of blood pressure, pulse rate and cholesterol. Cardiovascular disease and cardiology concept
Cardiovascular disease
Mineralys’ Hypertension Drug Drops Blood Pressure in Phase II/III, Setting Up Market Clash
March 10, 2025
 · 
2 min read
 · 
Dan Samorodnitsky